Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-324-5p antagomir
- Development stage
- Preclinical
- Lead developer
- Cincinnati Children's Hospital Medical Center
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal
01
Overview
miR-324-5p antagomir is a synthetic, locked-nucleic acid-modified antisense oligonucleotide designed to inhibit the microRNA miR-324-5p. In preclinical models of epilepsy, miR-324-5p antagomir has been shown to provide neuroprotection, reduce seizure susceptibility, and decrease seizure frequency, particularly in male mice. It acts by blocking miR-324-5p, which post-transcriptionally suppresses the voltage-gated A-type potassium channel Kv4.2 (KCND2). By inhibiting miR-324-5p, the antagomir prevents the downregulation of Kv4.2, thereby restoring potassium channel expression and reducing neuronal excitability. It has been investigated primarily in academic research settings, such as Cincinnati Children's Hospital Medical Center, for its therapeutic potential in temporal lobe epilepsy and genetic models of epilepsy (e.g., Cntnap2 knockout mice).
- Other names
- antagomir-324-5pantagomir324-5pantagomir 324-5pmiR-324-5p inhibitormiR324-5p inhibitormiR 324-5p inhibitor
Beyond the preview
Go deeper on miR-324-5p antagomir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-324-5p antagomir.